The following article features coverage from the ASCO Genitourinary Cancers Symposium 2022. Click here to read more of MPR‘s conference coverage.
Individuals with a history of e-cigarette smoking may be at increased risk of developing lung and bladder cancer, according to findings presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.
To examine the prevalence of lung and bladder cancer among individuals with various smoking histories, researchers examined data from the National Health Interview Survey (NHIS) database for the years 2016 to 2018. “Multivariable logistic regression analyses assessed possible association of various covariates with these cancers,” the researchers explained.
Findings demonstrated that all smoking histories were tied to a higher prevalence of bladder and lung cancer, when compared with individuals who never smoked. Cigarette smoking and e-cigarette smoking were also individually found to be associated with increased odds of being diagnosed with bladder cancer (odds ratio [OR], 2.476 [P ≤.001] and 1.577 [P ≤.001], respectively) or lung cancer (OR, 4.589 [P ≤.001] and 1.614 [P =.007], respectively) based on multivariable logistic regression models.
Additionally, individuals with a history of e-cigarette smoking were significantly younger when they received a bladder cancer diagnosis compared with those with no history of e-cigarette smoking (56.87±9.86 vs 65.00±12.60 years, respectively; P =.001).
Based on their findings, the study authors concluded that “additional studies are need to better define the public health effects of these novel and unregulated products.”
Herriges MJ, Pinkhasov R, Shapiro O, Jacob JM, Basnet A, Bratslavsky, et al. E-cigarette use and the risk of bladder and lung cancer. Presented at: ASCO-GU 2022; February 17-19, 2022; Abstract 443.